Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Unknown 2Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Hepatocellular 14Carcinoma, Non-Small-Cell Lung 9Colorectal Neoplasms 7Stomach Neoplasms 6Triple Negative Breast Neoplasms 5Esophageal Squamous Cell Carcinoma 4Cholangiocarcinoma 4Uterine Cervical Neoplasms 3Small Cell Lung Carcinoma 3Pancreatic Neoplasms 3Melanoma 3Urinary Bladder Neoplasms 2Recurrence 2Rectal Neoplasms 2Neoplasms 2Nasopharyngeal Carcinoma 2Lymphoma, Extranodal NK-T-Cell 2Liver Neoplasms 2Glioblastoma 2Carcinoma, Transitional Cell 2Breast Neoplasms 2Advanced Biliary Tract Cancer 2Urothelial Carcinoma Bladder 1Urologic Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Diseases 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Radiation Pneumonitis 1

Interventions

Sorafenib 9Radiofrequency Ablation 7Oxaliplatin 7Fluorouracil 6Doxorubicin 6Neoadjuvant Therapy 5toripalimab 4lenvatinib 4Injections 4Chemotherapy, Adjuvant 4Bevacizumab 4sintilimab 3pembrolizumab 3Ultrasonography 3Thalidomide 3Leucovorin 3Irinotecan 3Cisplatin 3tislelizumab 2durvalumab 2camrelizumab 2anlotinib 2Walking Speed 2Standard of Care 2Radiosurgery 2Oncolytic Virotherapy 2Metformin 2Liver Transplantation 2Laparoscopy 2Immunohistochemistry 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Liver Neoplasms × tislelizumab × Clear all
NCT06059885 2023-09-29

Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC

Beijing 302 Hospital

Phase 2 Unknown
60 enrolled
Gastrointestinal

Liver Neoplasms

NCT05339581 2022-04-27

iPLENTY-pvtt

RenJi Hospital

Phase NA Unknown
78 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡